Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- McFarland Clinic - Boone — Boone, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Iowa: - Research Site — Des Moines, Iowa
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Iowa: - University of Iowa Health Care — Waukee, Iowa
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Iowa: - Research Site — Des Moines, Iowa
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Iowa: - Mission Cancer + Blood - IMMC — Des Moines, Iowa
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Iowa: - Clinical Trial Site — Ames, Iowa
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
- UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
- Mercy Medical Center - Des Moines — Des Moines, Iowa
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Iowa: - Accellacare of McFarland — Ames, Iowa
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Iowa: - Local Institution - 0065 — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Sponsor: Radionetics Oncology
NCT ID: NCT06745804
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 in…
Sponsor: BeOne Medicines
NCT ID: NCT06756932
Sites in Iowa: - University of Iowa Hospitals and Clinics — Iowa City, Iowa
NA Recruiting Network
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to e…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06112613
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- Mission Cancer and Blood - Ankeny — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
Recruiting Academic/Other
The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner pla…
Sponsor: Corewell Health East
NCT ID: NCT05704062
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 4 Recruiting Academic/Other
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants wil…
Sponsor: University of Illinois at Chicago
NCT ID: NCT06169371
Sites in Iowa: - Iowa Holden Comprehensive Cancer Center — Iowa City, Iowa